CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

被引:1
作者
Maciocia, Nicola [1 ]
Wade, Brandon [1 ]
Maciocia, Paul [1 ]
机构
[1] UCL, Dept Haematol, Canc Inst, London, England
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; CHIMERIC ANTIGEN RECEPTOR; CHAIN CONSTANT-REGION; EXPRESSION; ANTIBODY; LYMPHOMA; 1ST-IN-HUMAN; FAMILY; CD22; CD19;
D O I
10.1182/bloodadvances.2023012263
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area.
引用
收藏
页码:913 / 923
页数:11
相关论文
共 88 条
[31]  
Hogan LE, 2022, J CLIN ONCOL, V40
[32]  
Horna P, 2024, Blood Cancer J, V14, P1
[33]   Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis [J].
Hu, Yongxian ;
Zhang, Mingming ;
Yang, Tingting ;
Mo, Zhuomao ;
Wei, Guoqing ;
Jing, Ruirui ;
Zhao, Houli ;
Chen, Rongrong ;
Zu, Cheng ;
Gu, Tianning ;
Xiao, Pingnan ;
Hong, Ruimin ;
Feng, Jingjing ;
Fu, Shan ;
Kong, Delin ;
Xu, Huijun ;
Cui, Jiazhen ;
Huang, Simao ;
Liang, Bin ;
Yuan, Xiaolin ;
Cui, Qu ;
Guo, Hongshan ;
Yu, Yunxian ;
Feng, Youqin ;
Jin, Chunxiang ;
Ren, Jiangtao ;
Chang, Alex H. ;
Wang, Dongrui ;
Huang, He .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (16) :1467-1480
[34]   Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study [J].
Hu, Yongxian ;
Zhou, Yali ;
Zhang, Mingming ;
Zhao, Houli ;
Wei, Guoqing ;
Ge, Wengang ;
Cui, Qu ;
Mu, Qitian ;
Chen, Gong ;
Han, Lu ;
Guo, Tingting ;
Cui, Jiazhen ;
Jiang, Xiaoyan ;
Zheng, Xiujun ;
Yu, Shuhui ;
Li, Xiaolong ;
Zhang, Xingwang ;
Chen, Mingxi ;
Li, Xiuju ;
Gao, Ming ;
Wang, Kang ;
Zu, Cheng ;
Zhang, Hao ;
He, Xiaohong ;
Wang, Yanbin ;
Wang, Dongrui ;
Ren, Jiangtao ;
Huang, He .
CELL RESEARCH, 2022, 32 (11) :995-1007
[35]  
Hultberg A, 2017, HEMATOL ONCOL, V35, P275, DOI [10.1002/hon.2438_148, DOI 10.1002/HON.2438_148]
[36]   Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model [J].
Ito, Asahi ;
Ishida, Takashi ;
Yano, Hiroki ;
Inagaki, Atsushi ;
Suzuki, Susumu ;
Sato, Fumihiko ;
Takino, Hisashi ;
Mori, Fumiko ;
Ri, Masaki ;
Kusumoto, Shigeru ;
Komatsu, Hirokazu ;
Iida, Shinsuke ;
Inagaki, Hiroshi ;
Ueda, Ryuzo .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1195-1206
[37]   CD1a on Langerhans cells controls inflammatory skin disease [J].
Kim, Ji Hyung ;
Hu, Yu ;
Tang Yongqing ;
Kim, Jessica ;
Hughes, Victoria A. ;
Le Nours, Jerome ;
Marquez, Elsa A. ;
Purcell, Anthony W. ;
Wan, Qi ;
Sugita, Masahiko ;
Rossjohn, Jamie ;
Winau, Florian .
NATURE IMMUNOLOGY, 2016, 17 (10) :1159-+
[38]   CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis [J].
Kim, Jinchul ;
Cho, Jinhyun ;
Lee, Moon Hee ;
Yoon, Sang Eun ;
Kim, Won Seog ;
Kim, Seok Jin .
BLOOD, 2024, 144 (06) :629-638
[39]   Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody [J].
Knox, S ;
Hoppe, RT ;
Maloney, D ;
Gibbs, I ;
Fowler, S ;
Marquez, C ;
Cornbleet, PJ ;
Levy, R .
BLOOD, 1996, 87 (03) :893-899
[40]  
Lee DM, 1998, J IMMUNOL, V160, P5749